Arcturus Therapeutics Holdings Inc. has released its financial results for the second quarter ending June 30, 2025. The company reported revenues of $28.3 million for the quarter, a decrease of $21.6 million from the same period in 2024. For the six months ending June 30, 2025, revenues stood at $57.7 million, down by $30.2 million compared to the previous year. These declines were primarily attributed to reduced revenue from the CSL collaboration due to lower supply agreement activity and decreased amortization of the upfront payment as KOSTAIVE® edges towards commercialization. Arcturus reported a net loss of approximately $9.2 million for the three-month period, compared to a net loss of $17.2 million in the second quarter of 2024. For the first half of 2025, the net loss was approximately $23.3 million, improving from a net loss of $44.0 million in the same period of the prior year. The company also provided updates on its research and development pipeline. Phase 2 interim data for the cystic fibrosis (ARCT-032) trial is expected to be presented in September, with full enrollment anticipated by the end of 2025. The Phase 3 trial design for OTC deficiency (ARCT-810) is expected to align with regulatory agencies in the first half of 2026. The seasonal flu (ARCT-2138) program showed positive Phase 1 results, while Phase 1 results for the BARDA pandemic flu (ARCT-2304) are expected later in 2025. Arcturus' cash, cash equivalents, and restricted cash were reported at $253.4 million as of June 30, 2025, with an extended cash runway into 2028 based on current pipeline and programs.